MedTrace Logo

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

NCT04032964 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2024-04-08

No results posted yet for this study

Summary

The study is aimed at evaluating the safety of L19TNF in combination with the most appropriate dose of doxorubicin.

Conditions

  • Soft Tissue Sarcoma

Interventions

DRUG

L19TNF

L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle

DRUG

DOXORUBICIN

Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle

Sponsors & Collaborators

  • Philogen S.p.A.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04032964 on ClinicalTrials.gov